Abstract:Objective To analyze the changing trend of CD4+T lymphocyte count and its influencing factors in HIV/AIDS patients receiving highly active antiretroviral therapy (HAART) in Hubei Province. Methods Adult patients receiving HAART after January 1, 2012 were screened, and the patients’ CD4+T lymphocyte counts at baseline and after 6 and 12 months of HAART and their influencing factors were analyzed by the general linear model and repeated measures analysis of variance(ANOVA). Results The mean values of CD4+T lymphocyte counts at baseline and after 6 and 12 months of HAART in 1,843 patients were (218.94±143.96)/μl, (334.31±188.62)/μl and (382.79±204.44)/μl respectively, and the differences were statistically significant (F=6,856.98, P=0.000). The main factors affecting the rise of CD4+T lymphocyte count after HAART were gender, age of receiving initial therapy, WHO clinical stage, initial treatment plan and baseline CD4+T lymphocyte count. Under the influence of gender, baseline CD4+T lymphocyte count, age of receiving initial therapy and initial treatment plan, the CD4+T lymphocyte count after the therapy increased linearly with time; moreover, the CD4+T lymphocyte count in female patients, patients receiving initial therapy at an earlier age, patients with higher baseline CD4+T lymphocyte count and patients receiving initial therapy with second-line drugs increased even faster. Under the influence of WHO clinical stage, the rising trend of CD4+T lymphocyte count after the therapy was in line with quadratic curve equation. The earlier the WHO clinical stage, the faster the increment. Conclusions The increase of CD4+T lymphocyte count in HIV/AIDS patients receiving HAART in Hubei Province is affected by many factors. HAART targeted for different patients should be carried out as early as possible so as to improve the efficacy of antiviral treatment and the quality of life of patients.